Outlook Therapeutics, Inc. Common Stock
OTLK Real Time Price USDRecent trades of OTLK by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by OTLK's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Buffer formulations for enhanced antibody stability Mar. 29, 2022
-
Patent Title: Modulation of charge variants in a monoclonal antibody composition Jun. 30, 2020
-
Patent Title: Buffer formulations for enhanced antibody stability Aug. 13, 2019
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of OTLK in WallStreetBets Daily Discussion
Recent insights relating to OTLK
Recent picks made for OTLK stock on CNBC
ETFs with the largest estimated holdings in OTLK
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view OTLK Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.